EUVIMEDEUVIMED entdecken
Open Access

Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody–drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer

Wenpeng Huang, Liming Li, Yuhan Zhou, Qi Yang, Jason C Mixdorf, Todd E Barnhart, Jessica C Hsu, Rachel J Saladin, Chihao Liu, Zachary T Rosenkrans, Jonathan W Engle, Jianbo Gao und 2 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07106-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Wenpeng Huang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng Dist., Beijing, 100034, China. Hauptthemen laut MEDLINE: Zirconium, Immunoconjugates, Triple Negative Breast Neoplasms, Antigens, Neoplasm. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Scientific and Technological Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital, the National Natural Science Foundation of China, The Henan Association for Science and Technology Youth Talent Support Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Trophoblast cell-surface antigen 2 (Trop2) is overexpressed in various solid tumors and contributes to tumor progression, while its expression remains low in normal tissues. Trop2-targeting antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), has shown efficacy in targeting this antigen. Leveraging the enhanced specificity of ADCs, we conducted the first immunoPET imaging study of Trop2 expression in gastric cancer (GC) and triple-negative breast cancer (TNBC) models using 89Zr-labeled Trodelvy ([89Zr]Zr-DFO-Trodelvy). This approach enables preclinical screening to identify patients who may benefit from targeted therapies. MATERIALS AND METHODS: Trop2 expression levels in GC and TNBC cell lines (NCI-N87, HGC-27, MDST8, and MDA-MB-468) were assessed via flow cytometry and immunofluorescence staining. Labeling of DFO-Trodelvy with 89Zr was performed in Na2CO3 buffer at pH 7 (37 °C, 1.5 h). In vitro stability was analyzed using radio-thin layer chromatography. Biological properties were evaluated through cell uptake, saturation binding assays, and biodistribution experiments. ImmunoPET imaging with [89Zr]Zr-DFO-Trodelvy was performed at various time points to confirm its in vivo targeting. Immunohistochemical and immunofluorescence analyses were conducted on tumor tissues from tumor-bearing mice. RESULTS: The radiochemical yield of [89Zr]Zr-DFO-Trodelvy exceeded 90%, with a radiochemical purity (RCP) greater than 99%. Trop2 expression was high in MDA-MB-468 and NCI-N87 cells, while it was low in MDST8 and HGC-27 cells. The KD values of [89Zr]Zr-DFO-Trodelvy were 9.44 nM for MDA-MB-468 and 3.51 nM for NCI-N87 cells. ImmunoPET imaging with [89Zr]Zr-DFO-Trodelvy provided clear visualization of tumor morphology in MDA-MB-468 and NCI-N87 models (n = 3) as early as 6 h post-injection. Tumor uptake of [89Zr]Zr-DFO-Trodelvy increased over time, peaking at 48 h (MDA-MB-468: 10.03 ± 1.26%ID/g; NCI-N87: 14.30 ± 2.09%ID/g), and was significantly higher than in the MDST8 (5.27 ± 0.71%ID/g) and HGC-27 (4.37 ± 0.54%ID/g) models. Co-injection with 2 mg of unlabeled Trodelvy significantly reduced uptake in NCI-N87 and MDA-MB-468 tumors (P < 0.001). A high target-to-non-target ratio was observed at 48 h, showing specific tumor uptake and minimal off-target accumulation. Fluorescence imaging further confirmed higher tumor uptake in the IRDye800CW-Trodelvy group compared to the IRDye800CW-Trodelvy-blocking group (P < 0.001). CONCLUSIONS: [89Zr]Zr-DFO-Trodelvy for immunoPET imaging in TNBC and GC tumor models demonstrated specific, rapid, and sustained accumulation in tumors with high Trop2 expression, allowing for noninvasive monitoring of Trop2 status. The increased tumor-to-background ratio observed in immunoPET imaging suggests strong potential for clinical translation. Additionally, optical imaging, with its superior spatial resolution compared to PET, was employed to aid in precise probe localization and potentially enhancing differentiation between healthy and malignant tissues during surgical procedures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ZirconiumImmunoconjugatesTriple Negative Breast NeoplasmsAntigens, NeoplasmStomach NeoplasmsCell Adhesion MoleculesRadioisotopesAntibodies, Monoclonal, HumanizedHumansAnimalsCell Line, TumorMiceFemaleTissue DistributionCamptothecin

Stichwörter der Autor:innen

Antibody–drug conjugateGastric cancerImmunoPETTriple-negative breast cancerTrodelvyTrop2Zr-89

Substanzen

ZirconiumImmunoconjugatesTACSTD2 protein, humanAntigens, NeoplasmZirconium-89Cell Adhesion MoleculesRadioisotopessacituzumab govitecanAntibodies, Monoclonal, HumanizedCamptothecin

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng Dist., Beijing, 100034, China.
  • Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China.
  • Henan Key Laboratory of Image Diagnosis and Treatment for Digestive System Tumor, Zhengzhou, 450052, Henan Province, China.
  • Departments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, WI, 53705, USA.
  • Carbone Cancer Center, University of Wisconsin - Madison, Madison, WI, 53705, USA.
  • Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China. cjr.gaojianbo@vip.163.com.

ORCID-Profile: Weibo Cai

Förderung

  • Scientific and Technological Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital
  • the National Natural Science Foundation of China
  • The Henan Association for Science and Technology Youth Talent Support Program
  • National High Level Hospital Clinical Research Funding
  • Henan Medical Science and Technology Research Program Joint Construction Project
  • NCI NIH HHS
  • Beijing Municipal Science & Technology Commission
  • The Key Research Project in Henan Universities

Zitieren

APA

Huang, W., Li, L., Zhou, Y., Yang, Q., Mixdorf, J. C., Barnhart, T. E., Hsu, J. C., Saladin, R. J., Liu, C., Rosenkrans, Z. T., Engle, J. W., Gao, J., Kang, L., & Cai, W. (2025). Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody–drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07106-4

Vancouver

Huang W, Li L, Zhou Y, Yang Q, Mixdorf JC, Barnhart TE, et al. Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody–drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07106-4

BibTeX
@article{Huang2025,
  author = {Huang, Wenpeng and Li, Liming and Zhou, Yuhan and Yang, Qi and Mixdorf, Jason C and Barnhart, Todd E and Hsu, Jessica C and Saladin, Rachel J and Liu, Chihao and Rosenkrans, Zachary T and Engle, Jonathan W and Gao, Jianbo and Kang, Lei and Cai, Weibo},
  title = {Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody–drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07106-4}
}
Kostenlos starten →